Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Allogene Therapeutics Inc (NQ: ALLO )

5.640 -0.160 (-2.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 724,110
Open 5.800
Bid (Size) 5.660 (2)
Ask (Size) 5.740 (1)
Prev. Close 5.800
Today's Range 5.600 - 5.850
52wk Range 4.420 - 17.49
Shares Outstanding 142,183,418
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-2.08%
-2.08%
1 Month
-11.32%
-11.32%
3 Month
-1.05%
-1.05%
6 Month
-35.62%
-35.62%
1 Year
-47.53%
-47.53%

More News

Read More
Where Allogene Therapeutics Stands With Analysts
Via Benzinga
The Latest Analyst Ratings for Allogene Therapeutics
Via Benzinga
Recap: Allogene Therapeutics Q1 Earnings
Via Benzinga
Where Allogene Therapeutics Stands With Analysts
Via Benzinga
Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
The 3 Best Stocks to Short in May 2023
Via InvestorPlace
7 Short-Interest Stocks to Target for Explosive Gains
Via InvestorPlace
As Feinstein Returns To Congress, Reports Of Her Stock Profits Upset Aaron Rodgers
Via Benzinga
Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Why Synaptics Shares Are Trading Lower By 17%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Zillow, Shopify, Datadog And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Xerox, Hubbell, Spotify And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
7 Short-Squeeze Stocks That Could Make You Rich
Via InvestorPlace
Consolidated Communications, CRISPR Therapeutics And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Allogene Therapeutics Announces Participation in Four Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
7 Short-Squeeze Stocks That Could Explode in April
Via InvestorPlace
Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Short Interest Update - Monday, March 27
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.